ELV
Elevance Health Inc
Elevance Health Inc historical holders
total: 16
Eagle Capital Management Elevance Health Inc transactions over time
- Total transactions:
- 25
- New positions:
- 1
- Added:
- 8
- Reduced:
- 16
- Held since:
- 2020 Q1
- Held for:
- 25 quarters
- Latest activity:
- 2026 Q1
Eagle Capital Management has been an institutional investor in Elevance Health Inc (ELV) since 2020 Q1. According to 2026 Q1 report, Eagle Capital Management holds 1,548,610 shares with a market value of roughly $453.36M representing 1.52% of their equity portfolio. The fund/company first acquired ELV in 2020 Q1, initially purchasing about 1.25M shares. Since the initial investment, Eagle Capital Management has made 24 more transactions in this position.
Does Eagle Capital Management still hold ELV?
Yes, Eagle Capital Management continues to hold Elevance Health Inc (ELV). According to their 2026 Q1 report, they maintain a position of 1,548,610 shares valued at approximately $453.36M, representing 1.52% of their equity portfolio.
When did Eagle Capital Management first invest in ELV?
Eagle Capital Management first invested in Elevance Health Inc (ELV) in 2020 Q1 at the reported quarter-end price of $227.04 per share, acquiring 1,248,860 shares in their initial purchase.
What is Eagle Capital Management's average cost basis for ELV?
Based on historical transaction data, Eagle Capital Management's estimated cost basis for Elevance Health Inc (ELV) is approximately $308.11 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $308.11
- Weighted AVG sell price:
- $456.27
ELV transactions history by Eagle Capital Management
25 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
1.52%
|
1,548,610
|
$292.75
|
$453,355,469
|
+2.96% (+44,559)
|
+0.04%
|
|
2025 Q4
|
1.64%
|
1,504,051
|
$350.55
|
$527,244,987
|
-4.30% (-67,640)
|
-0.08%
|
|
2025 Q3
|
1.62%
|
1,571,691
|
$323.12
|
$507,844,892
|
-0.21% (-3,259)
|
-0%
|
|
2025 Q2
|
2.02%
|
1,574,950
|
$388.96
|
$612,592,695
|
-0.66% (-10,398)
|
-0.01%
|
|
2025 Q1
|
2.52%
|
1,585,348
|
$434.96
|
$689,562,966
|
+1.33% (+20,732)
|
+0.03%
|
|
2024 Q4
|
2.10%
|
1,564,616
|
$368.90
|
$577,186,842
|
-2.23% (-35,614)
|
-0.05%
|
|
2024 Q3
|
3.09%
|
1,600,230
|
$520.00
|
$832,119,600
|
-0.52% (-8,286)
|
-0.02%
|
|
2024 Q2
|
3.23%
|
1,608,516
|
$541.86
|
$871,590,480
|
+2.70% (+42,280)
|
+0.08%
|
|
2024 Q1
|
3.14%
|
1,566,236
|
$518.54
|
$812,156,015
|
-2.75% (-44,233)
|
-0.1%
|
|
2023 Q4
|
3.22%
|
1,610,469
|
$471.56
|
$759,432,762
|
+16.32% (+225,991)
|
+0.45%
|
|
2023 Q3
|
2.79%
|
$435.42
|
+84.11% (+632,511)
|
|||
|
2023 Q2
|
1.50%
|
$444.29
|
-5.98% (-47,826)
|
|||
|
2023 Q1
|
1.68%
|
$459.81
|
-8.36% (-72,917)
|
|||
|
2022 Q4
|
2.12%
|
$512.97
|
-33.22% (-434,173)
|
|||
|
2022 Q3
|
2.70%
|
$454.24
|
-2.49% (-33,360)
|
|||
|
2022 Q2
|
2.81%
|
$482.58
|
-43.65% (-1,038,243)
|
|||
|
2022 Q1
|
3.95%
|
$491.22
|
-3.25% (-79,954)
|
|||
|
2021 Q4
|
3.40%
|
$463.54
|
-3.47% (-88,455)
|
|||
|
2021 Q3
|
2.79%
|
$372.80
|
-3.01% (-78,913)
|
|||
|
2021 Q2
|
2.86%
|
$381.80
|
+18.23% (+404,811)
|
|||
|
2021 Q1
|
2.46%
|
$358.95
|
-9.46% (-232,002)
|
|||
|
2020 Q4
|
2.50%
|
$321.09
|
-5.07% (-130,966)
|
|||
|
2020 Q3
|
2.49%
|
$268.59
|
+19.70% (+425,188)
|
|||
|
2020 Q2
|
2.08%
|
$262.98
|
+72.86% (+909,917)
|
|||
|
2020 Q1
|
1.18%
|
$227.04
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.